

## UNITED STATES PATENT AND TRADEMARK OFFICE

de

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/088,412	03/20/2002	Herbert Markl	02481.1781	5276
5487	7590 12/20/2005		EXAMINER	
ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC.			NAFF, DAVID M	
ROUTE 202-206			ART UNIT	PAPER NUMBER
MAIL CODE: D303A BRIDGEWATER, NJ 08807			1651 DATE MAILED: 12/20/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

p P	Application No.	Applicant(s)	
Advisory Action	10/088,412	MARKL ET AL.	
Before the Filing of an Appeal Brief	Examiner	Art Unit	
	David M. Naff	1651	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED 05 December 2005 FAILS TO PLACE THI			, , , ,
1. The reply was filed after a final rejection, but prior to or o			andonment of
this application, applicant must timely file one of the follo	owing replies: (1) an amendment. a	ffidavit, or other evidence	ence, which
places the application in condition for allowance; (2) a No	otice of Appeal (with appeal fee) in	compliance with 37 (	OFR 41.31; or
(3) a Request for Continued Examination (RCE) in comp	liance with 37 CFR 1.114. The repl	ly must be filed within	one of the
following time periods:			
a) The period for reply expiresmonths from the mailing of			
b) The period for reply expires on: (1) the mailing date of this Adv			er is later. In no
event, however, will the statutory period for reply expire later th Examiner Note: If box 1 is checked, check either box (a) or (b)			D WITHIN TWO
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date on	which the petition under 37 CFR 1.136(a	and the appropriate extension	ension fee have
been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened sta	and the corresponding amount of the fee.	ine appropriate extensite in (2)	on tee under 37 as set forth in (b)
above, if checked. Any reply received by the Office later than three month	s after the mailing date of the final rejection	on, even if timely filed, ma	ay reduce any
earned patent term adjustment. See 37 CFR 1.704(b).			
NOTICE OF APPEAL			
2. The Notice of Appeal was filed on <u>05 December 2005</u> . A			
of the date of filing the Notice of Appeal (37 CFR 41.37(a appeal. Since a Notice of Appeal has been filed, any repl			
AMENDMENTS	y must be med within the time pen	od sectoral mor or i	( + 1.07 (a).
3. ☑ The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brie	f will not be entered	hecause
(a) ☐ They raise new issues that would require further co			booddoo
(b) They raise the issue of new matter (see NOTE below		,,	
(c) They are not deemed to place the application in be		educing or simplifying	the issues for
appeal; and/or			
(d) They present additional claims without canceling a	-	ejected claims.	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1			
4. The amendments are not in compliance with 37 CFR 1.		ompliant Amendmen	(PTOL-324).
5. Applicant's reply has overcome the following rejection(s		Aimento filed amounds	tlina
<ol> <li>Newly proposed or amended claim(s) would be a the non-allowable claim(s).</li> </ol>	allowable il submitted in a separate	, timery nied amendn	ient canceling
7. For purposes of appeal, the proposed amendment(s): a)		ill be entered and an	explanation of
how the new or amended claims would be rejected is pro			•
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: <u>None</u> .			
Claim(s) objected to: Claim(s) rejected: <u>39-50,52-82 and 84-92</u> .			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
8.   The affidavit or other evidence filed after a final action, b	ut before or on the date of filing a l	Notice of Appeal will g	not be entered
because applicant failed to provide a showing of good ar	nd sufficient reasons why the affida	wit or other evidence	is necessary
and was not earlier presented. See 37 CFR 1.116(e).			
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to</li> </ol>			
showing a good and sufficient reasons why it is necessar			
10. The affidavit or other evidence is entered. An explanation	•		
REQUEST FOR RECONSIDERATION/OTHER		<b>,</b>	
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application	in condition for allowa	ance because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s)	
13. Other:		Du K	4/1-
			" V
		David M. Naff Primary Examiner	
		Art Unit: 1651	

Continuation of 3. NOTE: New issues for consideration are raised by amendments to claims 39, 45 and 70. In line 6, claim 39 has been amended to recite "culture vessel space". However, it appears this should be "culture fluid space" since the module cannot contain a culture vessel space, which is space in the culture vessel. In line 10 of the claim "the culture fluid space" does not have clear antecedent basis since line 6 recites "culture vessel space". In the last two lines of the claim, requiring introducing a second gas into the culture fluid "in the membrane module" is confusing since line 10 as amended requires culture fluid in the culture fluid space. Is introducing in the module in the culture fluid space or some other part of the module? Claim 45 is unclear as amended by requiring supplying the dialysis fluid space or the culture fluid space with the second gas since in claim 39, the second gas is introduced in the culture fluid in the module. Therefore, the second gas cannot be introduced only in the dialysis fluid space as encompassed by the alternative now required by claim 45. Amending claim 70 to require a dialysis membrane "having internal spaces", and an outlet being located in one of the internal spaces raises new issues for consideration since a membrane having internal spaces with an outlet in one internal space has not been previously claimed..

Continuation of 11. does NOT place the application in condition for allowance because: The arguments are unpersuasive. While Portner et al may disclose that single-vessel dialysis reactors were proposed as an alternative to the two-vessel arrangement, this does make unobvious supplying air to cells in the dialysis module in Fig 2a of Portner et al as suggested by Portner et al disclosing supplying air to cells in culture fluid in contact with a dialysis membrane in Fig 3a. There is seen nothing to lead one to believe air cannot be supplied to cells in culture fluid in the dialysis module of Fig 2a analogous to supplying air to cells in culture fluid in contact with a dialysis membrane in Fig 3a. Portner et al disclose the problem that suspended cells can suffer from oxygen limitation when pumped through the external module. Supplying oxygen to cells in the module would have been clearly an obvious way of overcoming the oxygen limitation problem since Fig 3a shows supplying oxygen to cells on one side of a dialysis membrane. The rejection in not based on supplying oxygen to the culture chamber of Fig 3b of Portner et al. but on supplying air the cells in the module of Fig 2a. Because the single-vessel reactor of Figs 3a and b may have certain advantages over the two-vessel reactor of Fig 2a does not make unobvious supplying air to the module of the two-vessel reactor for the expected function of the air to supply oxygen to cells in the module. The problems of the two-vessel reactor exposing the cells to stress due to pumping and requiring sophisticated control to balance liquid levels as disclosed by Portner et al will also be problems when using a two-vessel reactor as encompassed by the present claims. The claims require nothing that will overcome these problems. The claims address only the problem disclosed by Portner et al of cells suffering oxygen limitation in the module. This problem is addressed in the claims in the way suggested by Portner et al, i.e. by supplying air to the cells in the module.